Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.43 |
| ▸ | PGR | P06401 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1961059 | 0.94 | ALDH1A1 (0.54) | ALDH1A1TSHRLMNAUSP2ALOX15 | |
| SCHEMBL1960864 | 0.86 | ALDH1A1 (0.65) | ALDH1A1TSHRLMNAUSP2ALOX15 | |
| SCHEMBL2167190 | 0.86 | ALDH1A1 (0.58) | ALDH1A1TSHRLMNAUSP2ALOX15 | |
| SCHEMBL2166882 | 0.85 | TSHR (0.62) | ALDH1A1TSHRLMNAUSP2ALOX15 | |
| SCHEMBL2168830 | 0.85 | TSHR (0.62) | ALDH1A1TSHRLMNAUSP2ALOX15 | |
| SCHEMBL9710901 | 0.83 | ALDH1A1 (0.50) | ALDH1A1TSHRLMNAALOX15CHRM5 | |
| SCHEMBL2165971 | 0.81 | ALDH1A1 (0.41) | ALDH1A1TSHRLMNAUSP2ALOX15 | |
| SCHEMBL2165974 | 0.81 | ALDH1A1 (0.41) | ALDH1A1TSHRLMNAUSP2ALOX15 | |
| SCHEMBL2167770 | 0.81 | ALDH1A1 (0.41) | ALDH1A1TSHRLMNAUSP2ALOX15 | |
| SCHEMBL28890376 | 0.81 | CA2 (0.41) | ALDH1A1TSHRLMNAUSP2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383274-B2 | Nonaqueous electrolyte solution for lithium battery, lithium battery using same, and formyloxy group-containing compound used therein | UBE INDUSTRIES, LTD. (JP) | 2013-02-26 | — | — | US | claimed |
| EP-0324692-B1 | PROCESS FOR THE PREPARATION OF HYDROXYALKYLATING AGENTS, THE AGENTS AS PREPARED AND THEIR USE | RHONE-POULENC SANTE (FR) | 1992-11-25 | — | — | EP | claimed |
| US-5023361-A | Process for preparing hydroxyalkylating agents, the agents so obtained, and their use | RHONE-POULENC SANTE (FR) | 1991-06-11 | — | — | US | claimed |
| US-4925950-A | Process for preparing 1-hydroxyalkyl-5-nitroimidazole | RHONE-POULENC SANTE (FR) | 1990-05-15 | — | — | US | claimed |
| US-8383274-B2 | Nonaqueous electrolyte solution for lithium battery, lithium battery using same, and formyloxy group-containing compound used therein | UBE INDUSTRIES, LTD. (JP) | 2013-02-26 | — | — | US | disclosed |
| US-20110183199-A1 | NONAQUEOUS ELECTROLYTE SOLUTION FOR LITHIUM BATTERY, LITHIUM BATTERY USING SAME, AND FORMYLOXY GROUP-CONTAINING COMPOUND USED THEREIN | UBE INDUSTRIES, LTD. (JP) | 2011-07-28 | — | — | US | disclosed |
| US-5023361-A | Process for preparing hydroxyalkylating agents, the agents so obtained, and their use | RHONE-POULENC SANTE (FR) | 1991-06-11 | — | — | US | disclosed |
| US-4925950-A | Process for preparing 1-hydroxyalkyl-5-nitroimidazole | RHONE-POULENC SANTE (FR) | 1990-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183199-A1 | NONAQUEOUS ELECTROLYTE SOLUTION FOR LITHIUM BATTERY, LITHIUM BATTERY USING SAME, AND FORMYLOXY GROUP-CONTAINING COMPOUND USED THEREIN | HCN2, KCNN2, KCNB1 | ALDH1A1 2190/4885TSHR 3056/4885LMNA 793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.